Provided by Tiger Fintech (Singapore) Pte. Ltd.

Crinetics Pharmaceuticals Inc.

31.21
-0.0800-0.26%
Post-market: 31.210.00000.00%16:06 EDT
Volume:761.43K
Turnover:23.60M
Market Cap:2.92B
PE:-8.18
High:31.38
Open:31.35
Low:30.36
Close:31.29
Loading ...

Stifel Initiates Crinetics Pharmaceuticals at Buy With $60 Price Target

MT Newswires Live
·
25 Mar

Crinetics Pharmaceuticals Initiated at Buy by Stifel

Dow Jones
·
25 Mar

BRIEF-Crinetics Pharmaceuticals Announces March 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Reuters
·
11 Mar

Crinetics Pharmaceuticals Announces March 2025 Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
11 Mar

BUZZ-Morgan Stanley initiates Crinetics with 'outperform' on catalyst rich 2025

Reuters
·
08 Mar

Crinetics Pharmaceuticals Inc : Morgan Stanley Assumes Coverage With Overweight Rating; Price Target $70

THOMSON REUTERS
·
07 Mar

Promising Pipeline and Strategic Initiatives Drive Buy Rating for Crinetics Pharmaceuticals

TIPRANKS
·
07 Mar

Crinetics Pharmaceuticals Full Year 2024 Earnings: Revenues Disappoint

Simply Wall St.
·
01 Mar

Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans

Simply Wall St.
·
01 Mar

Crinetics Pharmaceuticals Is Maintained at Market Outperform by Citizens Capital Markets

Dow Jones
·
28 Feb

Crinetics Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
28 Feb

TD Cowen Sticks to Its Buy Rating for Crinetics Pharmaceuticals (CRNX)

TIPRANKS
·
28 Feb

Crinetics Pharmaceuticals Q4 Net Loss Narrows

MT Newswires Live
·
28 Feb

Earnings Flash (CRNS) Crinetics Pharmaceuticals Q4 Loss Per Share $0.88 vs. FactSet Est Loss $0.89

MT Newswires Live
·
28 Feb

Crinetics Pharmaceuticals Q4 GAAP EPS $(0.88), Inline

Benzinga
·
28 Feb

BRIEF-Crinetics Pharmaceuticals Q4 Net Income USD -80.595 Million

Reuters
·
28 Feb

Crinetics Pharmaceuticals Inc: for 2025, We Anticipate Our Cash Used in Operations to Be Between $340 and $380 Mln

THOMSON REUTERS
·
28 Feb

Is Crinetics Pharmaceuticals (CRNX) the Worst Performing Mid Cap Stock to Buy According to Analysts?

Insider Monkey
·
28 Feb

Investors push Crinetics Pharmaceuticals (NASDAQ:CRNX) 11% lower this week, company's increasing losses might be to blame

Simply Wall St.
·
27 Feb

Crinetics Pharmaceuticals Names Tobin Schilke CFO

MT Newswires Live
·
24 Feb